Last reviewed · How we verify
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Details
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 75 |
| Start date | Wed Aug 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
- TQC3721 suspension for inhalation
- TQC3721 matching placebo for inhalation
- Salbutamol sulfate inhalation aerosol
Countries
China